EU/3/15/1554: Orphan designation for the treatment of aneurysmal subarachnoid haemorrhage

Nimodipine

Overview

On 9 October 2015, orphan designation (EU/3/15/1554) was granted by the European Commission to Dr Stefan Blesse, Germany, for nimodipine for the treatment of aneurysmal subarachnoid haemorrhage.

The sponsorship was transferred to Granzer Regulatory Consulting & Services, in November 2019.

Key facts

Active substance
Nimodipine
Intended use
Treatment of aneurysmal subarachnoid haemorrhage
Orphan designation status
Positive
EU designation number
EU/3/15/1554
Date of designation
09/10/2015
Sponsor

Granzer Regulatory Consulting & Services
Kistlerhofstrasse 172c
81379 Munich
Germany
E-mail: info@reatapharma.com

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating